Non-refrigerated ritonavir tablet approved in Europe and the US
2 April 2010. Related: Antiretrovirals.
Antiretrovirals
FDA safety review of saquinavir (Invirase) and possible association with abnormal heart rhythms
2 April 2010. Related: Antiretrovirals.
FDA updates US label for darunavir (Prezista)
2 April 2010. Related: Antiretrovirals.
FDA safety announcement about ddI and non-cirrhotic portal hypertension
2 April 2010. Related: Antiretrovirals.
FDA label change for lopinavir/r (Kaletra)
2 April 2010. Related: Antiretrovirals.
FDA notice about drug interactions with etravirine (Intelence)
2 April 2010. Related: Antiretrovirals.
Once-daily darunavir/r monotherapy is suboptimal as initial regimen in treatment-naive people
21 February 2010. Related: Conference reports, Antiretrovirals.
GSK issues Dear Doctor letter in the US: fosamprenavir and cardiovascular risk
16 February 2010. Related: Antiretrovirals, Side effects.
Recent ARVs and the blood/brain barrier: CSF drug concentrations of darunavir/r and raltegravir
31 December 2009. Related: Conference reports, Antiretrovirals.
Tibotec issues Dear Doctor letter in Europe concerning severe etravirine reactions: three case reports
30 December 2009. Related: Treatment alerts, Antiretrovirals.
GSK and Pfizer launch joint HIV collaboration
30 December 2009. Related: Antiretrovirals.
First results of new integrase compound: GSK1349572
5 October 2009. Related: Conference reports, Antiretrovirals.
Raltegravir in treatment-naive patients
5 October 2009. Related: Conference reports, Antiretrovirals.
Nevirapine vs atazanavir/ritonavir in treatment-naive patients: ARTEN study
5 October 2009. Related: Conference reports, Antiretrovirals.
Darunavir/r monotherapy studies
5 October 2009. Related: Conference reports, Antiretrovirals.
Maraviroc results similar to efavirenz when analysed using more sensitive tropism test
5 October 2009. Related: Conference reports, Antiretrovirals.
Maximal suppression achieved with three drugs: no additional virological impact of raltegravir intensification
5 October 2009. Related: Conference reports, Antiretrovirals.
CD4 responses after viral suppression for more than 7 years on HAART
5 October 2009. Related: Antiretrovirals.
Raltegravir approved in Europe for treatment-naive patients
5 October 2009. Related: Antiretrovirals.
50mg and 100mg ritonavir doses achieve similar levels of saquinavir in Thai patients
5 October 2009. Related: Antiretrovirals.
Etravirine (Intelence) label change in the US due to severe hypersensitivity reactions
2 October 2009. Related: Antiretrovirals.
Four weeks lopinavir/r to cover functional monotherapy when stopping HAART
23 August 2009. Related: Conference reports, Antiretrovirals.
Efavirenz-related studies: genetics, smoking and TDM
23 August 2009. Related: Conference reports, Antiretrovirals.
Atazanavir: a suitable case for TDM?
23 August 2009. Related: Conference reports, Antiretrovirals.
Raltegravir approved in the US for treatment-naive patients: paranoia and anxiety added as side effects
22 August 2009. Related: Antiretrovirals.
EMEA positive opinion on using tipranavir and darunavir in younger patients
3 June 2009. Related: Antiretrovirals.
Lopinavir/r (Kaletra) cardiovascular risk requires FDA label changes
3 June 2009. Related: Antiretrovirals.
NEJM paper: NA-ACCORD cohort study on when to start treatment
3 June 2009. Related: Antiretrovirals.
NA ACCORD results support the importance of the START study: response to researchers
3 June 2009. Related: Antiretrovirals.
EMEA statement on abacavir and the risk of heart attack
3 June 2009. Related: Antiretrovirals.
Increased atazanavir dose recommended when used in combination with efavirenz or Atripla in naive patients
19 February 2009. Related: Antiretrovirals.
Summary of antiretroviral studies at Glasgow
18 February 2009. Related: Conference reports, Antiretrovirals.
EMEA approves once-daily darunavir/ritonavir (800mg/100mg) for treatment-naive patients in Europe
10 February 2009. Related: Antiretrovirals.
Maraviroc safety label changes included with US traditional approval
9 February 2009. Related: Antiretrovirals.
US approval of paediatric abacavir
9 February 2009. Related: Antiretrovirals.
EMEA supports extension of D:A:D study until at least 2012 and the new remit to include non-AIDS cancers and kidney disease
9 February 2009. Related: Antiretrovirals, Cancer and HIV.
Applications to approve non-refrigerated ritonavir submitted to EMEA and FDA
9 February 2009. Related: Antiretrovirals.
Studies of pipeline drugs: RDEA806, PRO140, bevirimat, elvucitabine
26 December 2008. Related: Conference reports, Antiretrovirals.
Other antiretroviral studies at ICAAC
26 December 2008. Related: Conference reports, Antiretrovirals.
Non alcoholic fatty liver disease (NAFLD) is common among HIV-positive patients
26 December 2008. Related: Conference reports, Antiretrovirals.
FDA approves new paediatric AZT dosing
26 December 2008. Related: Antiretrovirals.
US revisions to darunavir label include once-daily indication for naive patients
26 December 2008. Related: Antiretrovirals.
Baseline renal insufficiency and mortality risk in HIV-positive adults in Zambia
26 December 2008. Related: Antiretrovirals.
Inflammatory and coagulation biomarkers linked to mortality in large treatment interruption trial
26 December 2008. Related: Antiretrovirals.
Abacavir and heart disease: SMART study supports an abacavir-associated increased risk of cardiovascular disease
30 October 2008. Related: Conference reports, Antiretrovirals, Side effects.
EMEA state that animal studies support no increased risk of malignancy from contamination of nelfinavir (Viracept) with ethyl mesilate (EMS)
30 October 2008. Related: Antiretrovirals, Side effects.
Antiretrovirals calculated to extend life expectancy by 35 years
30 October 2008. Related: Antiretrovirals.
Etravirine approved in Europe
30 October 2008. Related: Antiretrovirals.
Abacavir label updated in the US on use of B-5701 testing and cardiovascular risk
30 October 2008. Related: Antiretrovirals.
Ritonavir label updated in the US relating to cardiac arrhythmia reported in high-dose studies
30 October 2008. Related: Antiretrovirals, Side effects.
Atazanavir label updated in the US relating to drug interactions with NNTRIs, hormonal contraceptives, midazolam, H2 receptor antagonists and other drugs
30 October 2008. Related: Antiretrovirals.
Pipeline antiretrovirals: IDX899, CHX157 and bevirimat
30 August 2008. Related: Conference reports, Antiretrovirals.
Renal tubular dysfunction with tenofovir-based HAART in four vertically infected adolescents
30 August 2008. Related: Conference reports, Antiretrovirals.
Boosted atazanavir approved in Europe as first-line therapy
30 August 2008. Related: Antiretrovirals.
BMS and Merck discontinue 100mg capsule formulation of efavirenz used for paediatric treatment
30 August 2008. Related: Antiretrovirals.
Saquinavir (Invirase) interactions with digoxin, garlic capsules, methadone, tipranavir and omeprazole: US label changes
30 August 2008. Related: Antiretrovirals.
US label changes for nevirapine paediatric solution
30 August 2008. Related: Antiretrovirals.
New US pediatric dosing for lopinavir/r
30 August 2008. Related: Antiretrovirals.
New US pediatric dosing for tipranavir/r
30 August 2008. Related: Antiretrovirals.
DSMB stops ACTG study due to suboptimal responses
30 August 2008. Related: Antiretrovirals.
Tibotec issue Dear Doctor letter and FDA require darunavir label change relating to hepatotoxicity
12 June 2008. Related: Antiretrovirals.
Atazanavir 300mg capsule available
12 June 2008. Related: Antiretrovirals.
Raltegravir approved in Scotland
12 June 2008. Related: Antiretrovirals.
Abacavir, ddI and risk of heart attack: additional published data and statements from the EMEA and FDA
1 June 2008. Related: Antiretrovirals.
Atazanavir/r vs lopinavir/r in treatment-naive patients: 48 week results
1 April 2008. Related: Conference reports, Antiretrovirals.